The quarter growth has been in-line with expectations, says Om Manchanda, CEO of Dr Lal PathLabs adding that some operational expenses will be seen in the next nine months.
CEO Om Manchanda expects planned expansion of central lab network in Kolkata and Lucknow will help Dr Lal PathLabs to sustain margins in FY17. Diagnostics space which has low penetration in India makes it a good pitch for companies like Dr Lal PathLab, according to Citi's Prashant Nair.